In re: Anagnostou et al. Serial No.: 09/525,797 Filed: March 15, 2000

Page 2

Listing of Claims

The following list of claims will replace all prior versions and listings of claims in the application.

1-11. (Canceled)

- 12. (Currently Amended) A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering cisplatin in conjunction with erythropoietin, wherein said erythropoietin is administered in an amount effective to enhance suppression of endothelial growth associated with administration of said cisplatin and wherein said subject is afflicted with or at risk of developing a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast or squamous cell cancer of the larynx.
- 13. (Previously Presented) A method according to claim 12, wherein said erythropoietin is administered concurrently with said cisplatin.
- 14. (Previously Presented) A method according to claim 12, wherein said erythropoietin is administered prior to said cisplatin.
- 15. (Previously Presented) A method according to claim 12, wherein said erythropoietin is administered after said cisplatin.

16-18. (Canceled)

- 19. (Previously Presented) A method according to claim 12, wherein said cisplatin is administered intravenously.
- 20. (Original) A method according to claim 12, wherein said erythropoietin is administered intraveneously.
- 21. (Currently Amended) A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering cisplatin in

In re: Anagnostou et al. Serial No.: 09/525,797 Filed: March 15, 2000

Page 3

conjunction with erythropoietin;

wherein said erythropoietin is administered in an amount of from about 750 Units per kilogram to about 2,000 Units per kilogram and said subject is afflicted with or at risk of developing a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast, or squamous cell cancer of the larynx.

22. (Canceled)

- 23. (Previously Presented) A method according to claim 21, wherein said erythropoietin is administered concurrently with cisplatin.
- 24. (Original) A method according to claim 23, wherein said cisplatin is administered intraveneously.
- 25. (Original) A method according to claim 24, wherein said erythropoietin is administered intraveneously.
- 26. (Previously Presented) A method according to claim 12, wherein said cisplatin is administered in a manner selected from the group consisting of intravenous, intramuscular, intraperitoneal, subcutaneous, intratumor, and intrapleural injection.

27-30. (Canceled)

- 31. (New) A method of treating a solid vascularized tumor according to claim 1, wherein the solid vascularized tumor is a cerebellar hemangioblastoma.
- 32. (New) A method of treating a solid vascularized tumor according to claim 1, wherein the solid vascularized tumor is a ductal carcinoma of the breast.

In re: Anagnostou et al. Serial No.: 09/525,797 Filed: March 15, 2000 Page 4

33. (New) A method of treating a solid vascularized tumor according to claim 1, wherein the solid vascularized tumor is a squamous cell cancer of the larynx.